This biotech company specializes in microcapsule development using proprietary microfluidics for drug encapsulation, enabling targeted delivery of therapeutics within muscles and tissues. Their platform technology enhances patient outcomes by providing a self-regulated mechanism for administering both existing and novel drugs.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of delivering therapeutics to musculoskeletal tissues often lack precision and sustained release, leading to potential systemic side effects and the need for frequent injections. Existing drug delivery systems do not effectively leverage the body's natural biomechanical forces to control drug release within articulating joints.
Solution
Mechano Therapeutics is developing mechano-activated microcapsules (MAMCs) that enable targeted and controlled drug delivery within musculoskeletal tissues. Their proprietary microfluidic technology encapsulates drugs within biodegradable microcapsules that release their payload in response to mechanical forces within the joint. This approach allows for on-demand drug release, sustained bioavailability, and reduced systemic exposure, improving therapeutic efficacy while minimizing potential side effects. The microcapsules, made from FDA-approved PLGA, can encapsulate a range of therapeutics, including small molecules, proteins, and biologics.
Target Audience
The primary target audience includes researchers and developers focused on musculoskeletal health, as well as clinicians seeking improved methods for delivering therapeutics to articulating joints.
Features
- Proprietary microfluidic technology for creating size-controlled microcapsules (50+ microns)
- Mechano-activation enables drug release based on mechanical forces of the joint
- Encapsulation of soluble drugs, proteins, and biologics within PLGA microcapsules
- Targeted local release minimizes systemic side effects
- Sustained bioavailability maintains drug concentrations within the therapeutic range
- Directive therapy improves drug efficacy in joint tissues